The assumption was that whatever the risks of legalizing therapeutic MDMA, the crisis of PTSD gripping the country (and doing ...

Federal health officials have declined to approve the psychedelic drug MDMA as a therapy for PTSD. Drugmaker Lykos ...

Drugmaker Lykos Therapeutics had asked the FDA to approve its MDMA capsules as part of a therapy regimen they argued could be a breakthrough for treating challenging cases of PTSD. Lykos said the ...

The US Food and Drug Administration's (FDA) decision not to approve midomafetamine-assisted therapy (MDMA-AT) for ...

In a previous blog on the use of psychedelics to treat mental health disorders, we reported that the US Food and Drug Administration (FDA) ...

Lykos Therapeutics filed an application for FDA approval of its version of MDMA-assisted therapy for PTSD in February 2024.

Critics addressed the elephant in the room during the FDA’s first public meeting on trauma since its decision to delay ...

In June 2024, an FDA advisory committee voted overwhelmingly against the idea that the relevant clinical trials had proved the efficacy of MDMA for the treatment of PTSD. Just as decisively ...

As Psychiatric Times reported, this decision puts on hold what could have been a landmark approval for the treatment of PTSD with MDMA, also known as midomafetamine. Despite the setback, Lykos ...

WASHINGTON (AP) — Federal health regulators on Friday declined to approve the psychedelic drug MDMA as a therapy for PTSD, a ...

It is considered to be more pleasure-inducing than other amphetamines, and for this reason, it has been a popular party drug. Some researchers call MDMA an “empathogen” or a “feeling enhancer.” PTSD ...

MDMA research has been widely publicized by combat veterans, who say limited PTSD treatment options have contributed to ...